North America Continuous Glucose Monitoring Market Outlook
The North America continuous glucose monitoring market size was valued at USD 6.56 billion in 2023. The market is further projected to grow at a CAGR of 14.5% between 2024 and 2032, reaching a value of USD 23.22 billion by 2032.
Continuous Glucose Monitoring: Introduction
Continuous Glucose Monitoring (CGM) systems are essential tools for real-time glucose monitoring, offering a significant advantage over traditional fingerstick testing by continuously tracking glucose levels through a sensor placed under the skin. These systems measure glucose in the interstitial fluid and transmit data to a receiver or a smart device, providing glucose readings every few minutes. This continuous feedback allows users to observe glucose trends and receive alerts for potential hypo- or hyperglycemia, aiding in better dietary and medication management. CGMs are increasingly used by individuals with type 1 and type 2 diabetes to enhance glycemic control and by healthcare providers for more accurate patient monitoring.
Get a Free Sample Report with Table of Contents –https://www.expertmarketresearch.com/reports/north-america-continuous-glucose-monitoring-market/requestsample
Key Trends in the North America Continuous Glucose Monitoring Market
The North America Continuous Glucose Monitoring (CGM) market is experiencing significant growth, driven by several key trends that reflect both technological innovations and shifts in healthcare practices:
- Technological Advancements: The CGM market is benefiting from rapid technological improvements that enhance the accuracy, usability, and integration capabilities of CGM devices. New sensor technologies provide more accurate glucose readings and longer wear time, reducing the need for frequent replacements and calibrations. Additionally, advancements in connectivity allow these devices to seamlessly integrate with smartphones and smartwatches, enabling easier monitoring and data management.
- Increasing Adoption Among Type 2 Diabetics: Traditionally used by individuals with type 1 diabetes, CGMs are increasingly being adopted by those with type 2 diabetes. This trend is spurred by a growing recognition of the benefits of real-time glucose data in managing lifestyle and medication adjustments, even in less intensive cases of diabetes.
- Healthcare Provider Support and Education: There is an increasing effort among healthcare providers to educate patients about the benefits of CGM systems. Providers are becoming more proactive in recommending CGMs as a part of diabetes management plans, influenced by positive patient outcomes and improvements in quality of life reported by CGM users.
- Insurance and Reimbursement Landscape: Changes in the insurance and reimbursement landscape have made CGMs more accessible to a broader range of patients. More insurance companies are covering CGM devices, especially as data continues to support their role in reducing overall healthcare costs by preventing complications and hospitalisations due to diabetes.
- Integrated Digital Health Solutions: There is a growing trend toward integrating CGM systems with other digital health tools, such as health apps and telemedicine platforms. These integrations allow for better chronic disease management by providing comprehensive health insights that can be remotely monitored by healthcare professionals.
- Consumer Demand for Wearable Health Technologies: The broader trend of increased consumer interest in wearable health technologies has also propelled the CGM market. As people become more proactive about managing their health, there is a higher demand for devices that offer detailed insights into one’s physiological conditions in real-time.
These trends indicate a vibrant and evolving CGM market in North America, characterised by technological innovation, expanded use cases, and an increasing alignment with consumer and healthcare provider needs. This market is poised for continued growth as it plays a crucial role in transforming diabetes management.
North America Continuous Glucose Monitoring Market Segmentation
Market Breakup by Component
- Sensors
- Transmitters
- Receivers
Market Breakup by Demography
- Child Population
- Adult Population
Market Breakup by End User
- Hospitals and Clinics
- Home Healthcare
- Others
Market Breakup by Country
- United States of America
- Canada
North America Continuous Glucose Monitoring Market Overview
In the North America Continuous Glucose Monitoring (CGM) market, the United States represents the larger segment, driven by a high prevalence of diabetes, significant investments in healthcare technology, and strong insurance coverage for CGM devices. The market benefits from continual technological advancements in CGM systems and their increasing integration with digital health platforms, which enhance patient engagement and data management. With a robust infrastructure for diabetes care and a growing trend towards proactive health management, the U.S. is poised for substantial growth in CGM adoption among individuals with both type 1 and type 2 diabetes.
In Canada, the CGM market is growing steadily, fueled by an increasing prevalence of diabetes and a supportive healthcare policy environment that emphasises preventive care and effective chronic disease management. The adoption of CGM technologies is further supported by governmental initiatives and healthcare providers who recognise the benefits of real-time glucose monitoring. This support is expected to drive continued market growth, making Canada an important contributor to the expansion of the North American CGM market. As more Canadians adopt CGM systems, the market is likely to see enhanced growth during the forecast period, supported by policy backing and increasing healthcare provider endorsements of CGM technology.
North America Continuous Glucose Monitoring Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbott Laboratories
Abbott Laboratories is a globally diversified healthcare company headquartered in Illinois, USA. It is renowned for its broad range of medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. Abbott is particularly noted for its leadership in the CGM market with the FreeStyle Libre system, which has revolutionised glucose monitoring by providing a less invasive and more user-friendly approach compared to traditional methods.
- Dexcom, Inc.
Based in San Diego, California, Dexcom, Inc. specialises in the design, development, and commercialisation of continuous glucose monitoring systems for use by people with diabetes. Known for its innovative sensor technology, Dexcom’s CGM systems are highly regarded for their accuracy and real-time glucose readings, which are critical for effective diabetes management. Dexcom continues to be a leader in the diabetes care market, pushing forward with next-generation technologies.
- Medtronic PLC
Medtronic PLC is one of the largest medical device companies in the world, headquartered in Dublin, Ireland. The company operates in various segments, including cardiac and vascular, minimally invasive therapies, restorative therapies, and diabetes. In the diabetes sector, Medtronic offers advanced CGM systems and integrated insulin pump technologies, providing comprehensive solutions that improve the lives of people living with diabetes.
- Senseonics, Inc.
Senseonics, Inc., headquartered in Maryland, USA, focuses on the development and commercialisation of the Eversense® system, a long-term implantable CGM system. This product distinguishes itself by offering continuous glucose monitoring for up to 90 days (about 3 months) via an under-the-skin sensor, a removable and rechargeable transmitter, and a convenient smartphone app for real-time data viewing, which significantly enhances user convenience and compliance.
- Byram Healthcare Centers, Inc.
Byram Healthcare, a subsidiary of Owens & Minor, Inc., is a leader in providing medical supplies delivered directly to consumers’ homes and is particularly strong in the diabetes supply segment. Headquartered in White Plains, New York, Byram offers a broad range of products and services that cater to the management of diabetes, including CGM systems. The company emphasises customer service, ensuring patients receive their necessary supplies conveniently and efficiently.
Other key players in the market include F. Hoffmann-La Roche Limited and others.
About Us:
Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.
Our high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today’s competitive market.
Don’t miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation’s future success by acquiring one of our Expert Market Research reports today.
Media Contact:
Company Name: Claight Corporation
Contact Person: Mark, Business Consultant
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
